CB2 Insights (CSE:CBII, OTCQB:CBIIF) (“CB2” or the “Company”), a leading data-driven company focused on bringing real-world evidence driven from the point-of-care to the medical cannabis community, today announced that it will begin a prospective trial with GL Brands (OTCQB: FRLF) through its U.S.-based hemp brand and key operating subsidiary, Green Lotus.  The study will assess the safety, efficacy and other health measures for patients using Green Lotus’ cannabidiol soft gel capsules when looking to treat anxiety.

“We are proud to have been approached by GL Brands to help advance their product research and development efforts using our vast network of clinical sites and knowledge and experience in conducting clinical trials,” said Prad Sekar, Chief Executive Officer, CB2 Insights.  “Cannabis licensed producers, product manufacturers and cannabis-focused pharmaceutical companies have all matured to the point of needing clinically-driven research to support the registration of their medical products.  Our tools and experience help formalize and expedite that process in a way that is aligned with traditional pharmaceutical products.”


Patients and Clinicians will be recruited for the study through the existing CB2 Insights clinical network which represents the largest medical cannabis patient registry in the US.  This ability to leverage CB2 Insights as a central source of patient recruitment for trials in an expedited manner helps generate measurable results in a more time-efficient manner; reducing the time needed to validate products that are being brought to market across a variety of indications.

Aside from its Clinical Services arm, CB2 Insights specializes as a Contract Research Organization (CRO) with services including growing patient registries, providing cannabis-specific data collection tools, designing clinical trials and managing research protocols for cannabis-based medicines.  The objective of the partnership is to determine the efficacy of orally administered CBD capsules for anxiety.  The trial will incorporate a multi-center experimental pre-test, post-test, non-randomized design and will monitor patients using the specified Green Lotus treatment over a 90-day period.

“Through our subsidiary brand, Green Lotus, we have brought to market one of the most wide-ranging lines of natural and organic hemp products that provide a full spectrum of remedies for consumers across North America suffering from multiple ailments,” said Carlos Frias, CEO, GL Brands.  “Our partnership with CB2 Insights will allow us to illustrate the effectiveness of our products across indications such as chronic pain, sleep disorders and anxiety.”

Both parties will utilize this study’s results to launch further investigation of Green Lotus products to extend development into new products for new indications. This agreement follows the announcement of the CB2 Insights being selected as the exclusive research technology partner of Drug Science to support the UK’s largest medical cannabis pilot program, TWENTY21, which provides validation for the need for more rigorous clinically-led testing of products to support more global, traditional healthcare adoption.

The outcome of the CB2 Insights and GL Brands partnership will be used in the further development of clinical trials, support in the validation of claims and efficacy of CBD treatment, and in the education of the medical community and patients on the integration of cannabinoid therapy.

“Data-driven innovation has always been a core focus for us at Merida Capital,” said Mitch Baruchowitz, Managing Partner, Merida Capital Partners. “We are now seeing scientifically-driven results accelerate the understanding and future value of cannabis-based medicine within a vertical that has long been needing validation from traditional pharmaceutical and healthcare players and the synergistic research between two of our portfolio companies illustrates this perfectly.”

The project has already commenced and will continue through patient recruitment, observations and trial close-out.

About CB2 Insights

CB2 Insights has a mission to mainstream medical cannabis into traditional healthcare. We are a research and technology company, offering a suite of data and technology solutions as a full service clinical CRO, specializing in Phase II, III and IV, post-marketing, observational and experimental trials in a range of therapeutic areas for sponsors worldwide.

CB2 Insights helps industry stakeholders create a strong value story with Real World Evidence, generation of safety and efficacy data, operating in two segments: clinical solutions and data solutions.

For more information please visit www.cb2insights.com.

About GL Brands Inc.:

GL Brands is a multinational hemp consumer packaged goods company that creates authentic, enduring and culturally relevant brands engaged in the development and sale of cannabis-derived wellness products. Through its premier brands Green Lotus™ and IrieCBD, GL Brands delivers a full portfolio of hemp and hemp-derived CBD products, including tinctures, softgels, gummies, capsules, sparkling beverages, vapes, flower and topical segments to promote greater wellness and balance, in the U.S. and throughout the world. For more information, please visit https://www.glbrands.com.

About Green Lotus™:

Green Lotus™ Hemp is a premium hemp products brand that provides responsibly produced, natural cannabinoid-rich products to consumers and businesses. The brand is veteran-led and powered by a diverse team dedicated to promoting a world where the restorative power of hemp is accessible to all people. For more information, please visit https://greenlotushemp.com.

Primary Contact:
Kim Nguyen
1.855.874.4999 ext. 120
kim.nguyen@cb2insights.com

Forward Looking Statements

Statements in this news release that are forward-looking statements are subject to various risks and uncertainties concerning the specific factors disclosed here and elsewhere in CB2’s filings with Canadian securities regulators. When used in this news release, words such as “will, could, plan, estimate, expect, intend, may, potential, believe, should,” and similar expressions, are forward-looking statements.

Forward-looking statements may include, without limitation, statements regarding the opportunity to provide services and software to the U.S. cannabis industry.

Although CB2 has attempted to identify important factors that could cause actual results, performance or achievements to differ materially from those contained in the forward-looking statements, there can be other factors that cause results, performance or achievements not to be as anticipated, estimated or intended, including, but not limited to: dependence on obtaining regulatory approvals; investing in target companies or projects which have limited or no operating history and are subject to inconsistent legislation and regulation; change in laws; reliance on management; requirements for additional financing; competition; hindering market growth and state adoption due to inconsistent public opinion and perception of the medical-use and recreational-use marijuana industry and; regulatory or political change.

There can be no assurance that such information will prove to be accurate or that management’s expectations or estimates of future developments, circumstances or results will materialize. As a result of these risks and uncertainties, the results or events predicted in these forward-looking statements may differ materially from actual results or events.

Accordingly, readers should not place undue reliance on forward-looking statements. The forward-looking statements in this news release are made as of the date of this release. CB2 disclaims any intention or obligation to update or revise such information, except as required by applicable law, and CB2 does not assume any liability for disclosure relating to any other company mentioned herein.

No securities regulator or exchange has reviewed, approved, disapproved, or accepts responsibility for the content of this news release.

Click here to connect with CB2 Insights (CSE:CBII) for an Investor Presentation.

Source

American cannabis sales hit US$17.5 billion in 2020, a research group’s new study shows.

Meanwhile, a Canadian cannabis producer began offering CBD beverages in the US, another move that shows how interested Canadians are in the overall US cannabis market at the moment.

Keep reading... Show less

An Emerging Markets Sponsored Commentary

Some pretty important news out of health and wellness; beverage and natural products company BevCanna Enterprises Inc. (CSE:BEV, Q:BVNNF, FSE:7BC) this week. For those of you following the Company with us, stay tuned.

Keep reading... Show less

As investors continue to prioritize cannabis opportunities in the US, market watchers expect mergers and acquisitions (M&A) to play a role in the future for Canadian companies.

A consolidation trend has been expected in the Canadian cannabis space for some time now based on the size of the market compared to the number of operations in the country.

Keep reading... Show less

The product will include polyphenols known to have significant health benefits.

BioHarvest Sciences Inc. (CSE: BHSC) (“BioHarvest” or the “Company”) has reached an important milestone in its development program of additional Nutraceuticals. The olive-based Nutraceutical product scheduled for market availability in the second half of 2022 will contain the following unique matrix of polyphenols: hydroxytyrosol, trosol, and verbascoside. These compounds are the major polyphenols in naturally grown olives and are responsible for the high antioxidant activity of olives and olive oil. Importantly, the BioHarvest olive-based Nutraceutical product will provide all the benefits of olives and olive oil with a low calorie count per serving.

Keep reading... Show less

Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco” or the “Company”), one of the largest vertically integrated multistate cannabis operators in the United States, announced today that it will report financial results for the fourth quarter and full year ended December 31 st , 2020 on Thursday March 25 th , 2021 before the market opens.

The Company will host a conference call and webcast to discuss its financial results and provide investors with key business highlights on Thursday March 25 th , 2021 at 8:30am Eastern Time (7:30am Central Time).

Keep reading... Show less